2022

1. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

   Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

2. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

   Lung Cancer, Vol. 173, pp. 83-93